Novavax Inc (NVAX) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Novavax inc   (NASDAQ: NVAX)


Novavax Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NVAX Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change -3.05 %
Seq. Revenue Change 20.46 %
Revenue In Millions $68.30
Gross Profit Margin 65.61 %
Gross Profit Margin Total Ranking # 720
Gross Profit In Millions $44.81
Y / Y Gross Profit Change -8.46 %
Seq. Gross Profit Change 5.55 %


Commenting Third Quarter 2026 Gross Profit Margin
Novavax Inc has managed to improve its Revenue sequentially to $68.30 millions by 20.46 % faster than Gross Profit increase of 5.55 % to $44.81 millions, this led to contraction in Gross Profit Margin to 65.61 %, but the Novavax Inc III. Quarter Gross Profit Margin remained above company average rate of 60.23%.


Observing third quarter 2026 results within Biotechnology & Pharmaceuticals industry 15 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 550 to 720.
Learn about Gross Margin
NVAX's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 16
Healthcare Sector # 128
Overall # 714

Gross Profit Margin Statistics
High Average Low
97.88 % 60.23 % 18.44 %
(Mar 31 2025)   (Mar 31 2012)


NVAX Gross Income Trends • More of NVAX's Profitabilty Ratios • NVAX Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
NVAX's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
NVAX's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for NVAX's Competitors
Gross Profit Margin Profit Margin for Novavax Inc 's Suppliers
Gross Profit Margin Profit Margin for NVAX's Customers

You may also want to know
NVAX's Annual Growth Rates NVAX's Profitability Ratios NVAX's Asset Turnover Ratio NVAX's Dividend Growth
NVAX's Roe NVAX's Valuation Ratios NVAX's Financial Strength Ratios NVAX's Gross Profit Growth
NVAX's Roa NVAX's Inventory Turnover Ratio NVAX's Growth Rates NVAX's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Revolution Medicines Inc   99.83 %$ 197.232  Millions$ 197.559  Millions
Immunocore Holdings Plc  99.34 %$ 101.546  Millions$ 102.222  Millions
Biocryst Pharmaceuticals Inc   99.13 %$ 178.718  Millions$ 180.292  Millions
Denali Therapeutics Inc   98.92 %$ 17.586  Millions$ 17.778  Millions
Scholar Rock Holding Corp  98.60 %$ 0.562  Millions$ 0.570  Millions
Neurocrine Biosciences Inc   97.63 %$ 1,096.100  Millions$ 1,122.700  Millions
Immunitybio inc   97.36 %$ 47.550  Millions$ 48.841  Millions
Exelixis Inc   96.02 %$ 632.463  Millions$ 658.696  Millions
Alpha Cognition Inc.  93.80 %$ 7.295  Millions$ 7.777  Millions
Ginkgo Bioworks Holdings Inc   93.48 %$ 25.905  Millions$ 27.711  Millions
Tarsus Pharmaceuticals Inc   92.86 %$ 180.675  Millions$ 194.569  Millions
Pelthos Therapeutics Inc   89.21 %$ 13.734  Millions$ 15.395  Millions
Lenz Therapeutics Inc   86.58 %$ 2.930  Millions$ 3.384  Millions
Halozyme Therapeutics Inc   83.27 %$ 410.499  Millions$ 492.974  Millions
X4 Pharmaceuticals Inc  81.68 %$ 2.287  Millions$ 2.800  Millions
Gilead Sciences Inc   81.07 %$ 6,729.000  Millions$ 8,300.000  Millions
Atara Biotherapeutics Inc   78.35 %$ 0.959  Millions$ 1.224  Millions
Adaptive Biotechnologies Corporation  76.24 %$ 63.969  Millions$ 83.902  Millions
Moderna Inc   75.78 %$ 995.000  Millions$ 1,313.000  Millions
Vericel Corporation  73.34 %$ 62.610  Millions$ 85.371  Millions
Biogen Inc   73.31 %$ 2,055.700  Millions$ 2,804.100  Millions
Amgen Inc   73.10 %$ 7,577.000  Millions$ 10,365.000  Millions
Coherus Oncology inc   71.33 %$ 10.182  Millions$ 14.274  Millions
Adma Biologics Inc   70.81 %$ 99.917  Millions$ 141.102  Millions
Sana Biotechnology Inc   68.80 %$ 25.466  Millions$ 37.012  Millions
Novavax inc   65.61 %$ 44.810  Millions$ 68.298  Millions
Bio techne Corp  65.60 %$ 196.623  Millions$ 299.712  Millions
Protalix Biotherapeutics inc   64.08 %$ 14.049  Millions$ 21.925  Millions
Elutia Inc   61.74 %$ 0.702  Millions$ 1.137  Millions
Iovance Biotherapeutics inc   60.46 %$ 73.441  Millions$ 121.469  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.